Abstract
Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Current Pharmaceutical Design
Title: Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Volume: 14 Issue: 36
Author(s): Carlo Bifulco, Katy McDaniel, Lin Leng and Richard Bucala
Affiliation:
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Abstract: Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Export Options
About this article
Cite this article as:
Bifulco Carlo, McDaniel Katy, Leng Lin and Bucala Richard, Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898608
DOI https://dx.doi.org/10.2174/138161208786898608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Current Computer-Aided Drug Design The Immunohistochemical Expression of the E-Cadherin, Alpha-Catenin,Beta-Catenin and Gamma Catenin Proteins in Epithelial Ovarian Tumours: Relationship with Clinicopathologic Parameters and Patient Survival
Current Women`s Health Reviews Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets Modified Alginate Beads for Mucoadhesive Drug Delivery System: An Updated Review of Patents
Recent Patents on Drug Delivery & Formulation The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medicinal Chemistry